10-Q: Elevance Health Reports Q2 Earnings Decline Amid Rising Medical Costs and Lower Star Ratings, Despite Revenue Growth

Elevance Health reported a decrease in net income and diluted earnings per share for the second quarter and first half of 2025, primarily due to higher medical cost trends and increased financial instrument losses, despite significant operating revenue growth.

Summary

• Total operating revenue increased by 14.3% to $49,421 million for the three months ended June 30, 2025, and by 14.8% to $98,186 million for the six months ended June 30, 2025, driven by premium rate increases, recent acquisitions, and growth in Medicare Advantage and Individual ACA membership.
• Net income decreased by 24.2% to $1,744 million for the three months ended June 30, 2025, and by 13.7% to $3,928 million for the six months ended June 30, 2025.
• Diluted shareholders' earnings per share (EPS) was $7.72 for the three months ended June 30, 2025, a 21.6% decrease from $9.85 in the prior year, and $17.33 for the six months ended June 30, 2025, a 10.9% decrease from $19.44.
• Operating cash flow for the six months ended June 30, 2025, increased to $3,071 million from $2,425 million in the prior year, primarily due to favorable working capital impacts.
• Medical membership decreased by 0.3% to 45.6 million members as of June 30, 2025, primarily due to attrition in Medicaid membership (down 3.3%) and Commercial Fee-Based business (down 0.3%), partially offset by growth in Medicare Advantage (up 11.0%) and Individual ACA businesses (up 5.2%).
• The benefit expense ratio increased to 88.9% for the three months ended June 30, 2025 (from 86.3%), and to 87.7% for the six months ended June 30, 2025 (from 85.9%), primarily due to higher medical cost trends in Medicaid and Individual/Small Group ACA plans.
• The operating expense ratio decreased to 10.1% for the three months ended June 30, 2025 (from 11.7%), and to 10.5% for the six months ended June 30, 2025 (from 11.6%), driven by operating expense leverage and disciplined cost management.
• Net losses on financial instruments increased significantly to $131 million for the three months ended June 30, 2025 (from $85 million), and to $595 million for the six months ended June 30, 2025 (from $246 million), mainly due to higher losses on other invested assets.
• The company completed acquisitions of Centers Plan for Healthy Living LLC and CareBridge in December 2024, aligning with strategic growth in Health Benefits and Carelon Services segments.
• A gain on sale of business of $240 million was recognized in the three and six months ended June 30, 2024, from the sale of life and disability businesses.
• The 2023-2024 Business Efficiency Program was finalized as of December 31, 2024, with remaining cash outlays for personnel-related costs expected through 2025.
• The company's 2025 Medicare Advantage Star Ratings reflect that 38% of members were in plans rated at least 4.0 Stars or higher, a decrease from 53% in 2024, which is expected to result in a reduction of approximately $183 million in 2026 operating revenue.
• The company recognized an estimated payment obligation of $666 million in September 2024 for the Provider Settlement Agreement in the Blue Cross Blue Shield Antitrust Litigation.
• Favorable development in medical claims payable for the six months ended June 30, 2025, was $1,065 million, primarily from trend factors in late 2024 developing more favorably than expected.
• The consolidated debt-to-capital ratio was 40.8% as of June 30, 2025, down from 43.0% at December 31, 2024.
• Cash, cash equivalents, and investments totaled $35,879 million at June 30, 2025, an increase of $163 million since December 31, 2024.
• The company repurchased 3.2 million shares for $1,259 million during the six months ended June 30, 2025, with $8,041 million remaining under the authorization.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company achieved strong revenue growth and improved operating efficiency, the significant decline in net income and EPS, coupled with rising medical costs and a notable drop in Medicare Advantage Star Ratings, indicates underlying profitability challenges and future revenue headwinds. The ongoing legal proceedings also add a layer of uncertainty.

Positives

• Total operating revenue increased significantly by 14.3% for the three months and 14.8% for the six months ended June 30, 2025, demonstrating strong top-line growth.
• Operating cash flow increased by $646 million to $3,071 million for the six months ended June 30, 2025, indicating healthy cash generation from operations.
• Medicare Advantage membership grew by 11.0% and Individual ACA membership by 5.2%, contributing to overall revenue growth.
• CarelonRx operating revenue increased by 21.3% for the three months and 23.3% for the six months, with operating gain increasing by 7.8% and 11.6% respectively, reflecting strong performance in pharmacy services.
• Carelon Services operating revenue surged by 63.7% for the three months and 63.4% for the six months, with operating gain increasing by 92.3% and 78.9% respectively, driven by acquisitions and expansion of risk-based capabilities.
• The operating expense ratio improved by 160 basis points for the three months and 110 basis points for the six months ended June 30, 2025, indicating disciplined cost management and operating leverage.
• The company maintained a strong financial condition and liquidity position with $35,879 million in cash, cash equivalents, and investments.
• The debt-to-capital ratio improved to 40.8% at June 30, 2025, from 43.0% at December 31, 2024, indicating reduced leverage.
• A favorable out-of-period settlement of $209 million with a value-based care provider contributed to a release of $129 million from the allowance for doubtful accounts.
• The company was in compliance with all debt covenants under its 5-Year Facility as of June 30, 2025.

Negatives

• Net income decreased by 24.2% for the three months and 13.7% for the six months ended June 30, 2025, indicating a decline in profitability.
• Diluted shareholders' earnings per share (EPS) decreased by 21.6% for the three months and 10.9% for the six months ended June 30, 2025.
• Net losses on financial instruments increased significantly to $131 million for the three months and $595 million for the six months ended June 30, 2025, primarily due to higher losses on other invested assets.
• The benefit expense ratio increased by 260 basis points for the three months and 180 basis points for the six months ended June 30, 2025, primarily due to higher medical cost trends in Medicaid and Individual/Small Group ACA plans.
• Medicaid membership declined by 3.3% and Commercial Fee-Based membership by 0.3%, partially offsetting growth in other segments.
• The company's 2025 Medicare Advantage Star Ratings decreased, with only 38% of members in plans rated at least 4.0 Stars or higher, down from 53% in 2024, which is expected to reduce 2026 operating revenue by approximately $183 million.
• Interest expense increased due to senior secured notes issuances in late 2024, and amortization of intangible assets increased due to fourth-quarter 2024 acquisitions.
• The effective income tax rate increased to 23.9% for the three months ended June 30, 2025, due to the non-recurrence of a favorable uncertain tax position resolution from the prior year.

Risks

• Trends in healthcare costs and utilization rates, including changes in service levels, regulatory changes, population aging, health status, epidemics, pandemics, medical technology advances, new high-cost prescription drugs, provider contracting inflation, labor costs, and healthcare fraud, waste, and abuse, can cause variance from estimates.
• The ability to secure and implement sufficient premium rates is crucial, as pricing may not adequately reflect current underlying healthcare cost trends due to timing lags.
• The impact of new or changes in existing federal, state, and international laws or regulations, including those impacting healthcare, insurance, and pharmacy services, or their enforcement or application, could adversely affect the business.
• Cyber-attacks or other privacy or data security incidents, or failure to comply with privacy, data, or security laws/regulations, including related investigations, claims, or litigation, pose significant risks.
• Failure to effectively maintain and modernize information systems, or failure of information systems or technology (including artificial intelligence) to operate as intended, could disrupt operations.
• Failure to effectively maintain the availability and integrity of data could lead to operational and reputational damage.
• Changes in economic and market conditions, as well as regulations, may negatively affect liquidity and investment portfolios.
• Competitive pressures and the ability to adapt to industry changes and implement strategic growth opportunities are ongoing challenges.
• Risks and uncertainties regarding Medicare and Medicaid programs, including non-compliance with complex regulations, could result in penalties or financial recoveries.
• The ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services (CMS) Star Ratings and other quality scores, and funding risks with respect to revenue received from participation therein, directly impact financial performance.
• A negative change in the healthcare product mix could adversely affect profitability.
• Costs and other liabilities associated with litigation, government investigations, audits, or reviews, including the ongoing Blue Cross Blue Shield Antitrust Litigation and Medicare Risk Adjustment Litigation, could have a material adverse effect.
• The ability to contract with providers on cost-effective and competitive terms is essential for managing benefit expense.
• Risks associated with providing healthcare, pharmacy, and other diversified products and services, including medical malpractice or professional liability claims and non-compliance with the pharmacy services agreement with CaremarkPCS Health, L.L.C. (CVS), could lead to liabilities.
• The effects of any negative publicity related to the health benefits industry in general or the company in particular could harm reputation and business.
• Risks associated with mergers, acquisitions, joint ventures, and strategic alliances, including integration challenges and valuation risks, could impact financial results.
• Possible impairment of the value of intangible assets if future results do not adequately support goodwill and other intangible assets could lead to significant write-downs.
• Possible restrictions in the payment of dividends from subsidiaries and increases in required minimum levels of capital could limit financial flexibility.
• The ability to repurchase shares of common stock and pay dividends depends on cash flow, earnings, and other considerations.
• The substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact access to or further increase the cost of financing pose financial risks.
• A downgrade in financial strength ratings could adversely impact business, liquidity, and borrowing costs.
• Events that may negatively affect licenses with the Blue Cross and Blue Shield Association could severely impact market access.
• Intense competition to attract and retain employees could increase labor costs and affect operational efficiency.
• Risks associated with international operations, though immaterial to total consolidated revenues, could still present challenges.
• Various laws and provisions in governing documents may prevent or discourage takeovers and business combinations.
• The budget reconciliation legislation of 2025, 'One Big Beautiful Bill Act' (OBBBA), could impact Medicaid renewal/eligibility rules, work requirements, state directed payments, provider taxes, cost sharing, home equity thresholds, and HHS authority over waivers.
• The 'Marketplace Integrity and Affordability Regulation' modifies ACA exchange open enrollment periods and eligibility for premium tax credits.
• Final regulations related to mental health parity will require administrative and operational changes, with litigation challenging these regulations.
• The expiration of enhanced Premium Tax Credits (PTC) at the end of 2025, if not extended by Congress, could have a material adverse effect on Individual Public Exchange enrollment and continuity of coverage.
• CMS plans to substantially increase the scale and pace of Risk Adjustment Data Validation (RADV) audits of Medicare Advantage plans, which could adversely affect financial condition and results of operations.

Future Outlook

The company expects full-year results to differ from interim estimates due to the seasonal nature of its business and market conditions. Future regulatory guidance is anticipated for the 'One Big Beautiful Bill Act' (OBBBA) provisions, which have effective dates in 2027 and 2028. The expiration of enhanced Premium Tax Credits (PTC) at the end of 2025, if not extended, could materially impact the Individual Public Exchange enrollment. CMS plans to significantly increase the scale and pace of Risk Adjustment Data Validation (RADV) audits of Medicare Advantage plans, which could adversely affect financial results. The company expects to mitigate the financial impact of lower 2025 Star Ratings on 2026 operating revenue through strategies like contract diversification, operating expense efficiencies, capital deployment alternatives, and network enhancements. The remaining $8,041 million authorized for common stock repurchases is expected to be utilized over a multi-year period. The company believes that current cash, future operating cash receipts, investments, and available credit facilities will be adequate to fund expected cash disbursements and future operations.

Management Comments

• Gail K. Boudreaux, President and Chief Executive Officer, and Mark B. Kaye, Executive Vice President and Chief Financial Officer, certified that the Form 10-Q report fully complies with the requirements of the Securities Exchange Act of 1934 and fairly presents the financial condition and results of operations.
• Management implemented the 2023-2024 Business Efficiency Program to enhance operating efficiency, refine investment focus, and optimize physical footprint, with cash outlays related to personnel-related costs expected through 2025.

Industry Context

The healthcare industry is experiencing significant medical cost trends driven by increased utilization, regulatory changes, an aging population, and the introduction of new high-cost prescription drugs. Elevance Health is actively managing these trends through various medical management programs and benefit design changes. Membership shifts, particularly from Medicaid due to redetermination processes, are impacting morbidity and increasing medical cost trends across the market. The company is navigating a complex regulatory landscape with new legislation like the 'One Big Beautiful Bill Act' (OBBBA) and the 'Marketplace Integrity and Affordability Regulation' impacting Medicaid and ACA markets. The Inflation Reduction Act of 2022 continues to influence the business through extended Premium Tax Credits and future drug price negotiation in Medicare. The pharmacy services sector, represented by CarelonRx, is seeing higher script utilization. The company's performance is also influenced by CMS Star Ratings, which directly affect Medicare Advantage bonus payments, and ongoing litigation related to antitrust and risk adjustment practices, reflecting broader industry challenges and scrutiny.

Comparison to Industry Standards

• The increase in medical cost trends, particularly in Medicaid and Individual ACA businesses, aligns with a market-wide increase in morbidity observed following Medicaid redetermination processes, indicating a broader industry challenge.
• The company's operating expense ratio improvement, driven by disciplined cost management and operating leverage, suggests effective internal efficiency compared to general industry pressures.
• The decline in Medicare Advantage Star Ratings for 2025 (used for 2026 payments) to 38% of members in 4.0+ Star plans, from 53% in 2024, indicates a performance dip relative to its own prior year and potentially some competitors, impacting future revenue.
• The ongoing Blue Cross Blue Shield Antitrust Litigation and Medicare Risk Adjustment Litigation are significant legal challenges common to large health insurers, reflecting the complex regulatory and competitive environment in the U.S. healthcare market, similar to cases faced by UnitedHealth Group (Optum), CVS Health (Aetna), and Cigna (Evernorth Health Services).

Corporate Governance

Legal Proceedings

• Blue Cross Blue Shield Antitrust Litigation: The company is a defendant in a multi-district proceeding alleging horizontal allocation of geographic markets and other antitrust violations. A Subscriber Settlement Agreement became effective in June 2024, with the company's payment of $604 million. A Provider Settlement Agreement, with an estimated payment obligation of $666 million for the company, received preliminary approval in December 2024, with a Final Fairness Hearing scheduled for July 29, 2025. Several follow-on cases from entities that opted out of these settlements are ongoing, which the company intends to vigorously defend.
• Medicare Risk Adjustment Litigation: The U.S. Department of Justice filed a civil lawsuit in March 2020, alleging false certification of diagnosis data submitted to CMS for risk-adjustment purposes and knowing failure to delete inaccurate diagnosis codes, leading to alleged overpayments. Fact discovery is ongoing with a current deadline of October 9, 2025 (expected to be extended), and expert discovery deadline of June 18, 2026. The company intends to vigorously defend this suit.

Related Party Transactions

• Mosaic Health: The company holds a minority interest (approximately 40%) in Mosaic Health, a joint venture with Clayton, Dubilier & Rice. The company provided a term loan of $200 million and a revolving credit facility of up to $500 million to Mosaic Health, with $188 million net receivable at June 30, 2025. The company recognized $9 million in interest income from this arrangement during the six months ended June 30, 2025. Mosaic Health provided care delivery and enablement services to Elevance Health subsidiaries amounting to $171 million (Q2 2025) and $346 million (YTD Q2 2025), reported in benefit expense.
• Liberty Dental: The company holds an equity method investment in Liberty Dental. In December 2024, the company committed to provide funding of up to $250 million in mandatorily redeemable preferred equity shares, with $146 million disbursed as of June 30, 2025. Liberty Dental provided services to the company's Medicare Advantage members under a capitated arrangement amounting to $146 million (Q2 2025) and $292 million (YTD Q2 2025), reported in benefit expense.

Stakeholder Impact

• Shareholders: Experienced a decrease in net income and EPS, but benefited from continued common stock repurchases ($1,259 million YTD Q2 2025) and consistent quarterly dividends of $1.71 per share. The decline in Star Ratings could impact future shareholder value.
• Members/Customers: Faced premium rate increases in Health Benefits. Medicaid members experienced attrition due to eligibility redeterminations. Medicare Advantage members are impacted by lower Star Ratings, which could affect future plan benefits or quality perceptions. CarelonRx and Carelon Services continue to provide pharmacy and healthcare services.
• Employees: The 2023-2024 Business Efficiency Program included staff reductions and relocation of job functions, with associated cash outlays continuing through 2025.
• Providers: A favorable out-of-period settlement with a value-based care provider was realized. The Provider Settlement Agreement in the antitrust litigation will require monetary payments and non-monetary terms, including expanded contracting opportunities and technological enhancements to the BlueCard program.
• Creditors: The company maintained a strong financial condition, reduced its debt-to-capital ratio, and remained in compliance with all debt covenants, indicating continued financial stability for creditors.

Next Steps

• The Final Fairness Hearing for the Provider Settlement Agreement in the Blue Cross Blue Shield Antitrust Litigation is scheduled for July 29, 2025.
• Fact discovery in the Medicare Risk Adjustment Litigation is ongoing with a current deadline of October 9, 2025, which is expected to be extended.
• The final expert discovery deadline in the Medicare Risk Adjustment Litigation is currently June 18, 2026.
• Cash outlays related to personnel-related costs from the 2023-2024 Business Efficiency Program are expected to be paid through 2025.
• Additional federal and state guidance is expected to be issued to implement the 'One Big Beautiful Bill Act' (OBBBA) provisions, most of which have effective dates in 2027 and 2028.
• The company will continue to evaluate the effects of ASU 2024-03 on its consolidated financial statements and related disclosures, effective for fiscal years beginning after December 15, 2026.
• The company expects to mitigate the financial impact of lower 2025 Star Ratings on 2026 operating gain and net income per share through various strategies such as contract diversification, operating expense efficiencies, capital deployment alternatives, and network enhancements.
• The company expects to utilize the remaining $8,041 million authorized for common stock repurchases over a multi-year period.
• The company may access capital markets and issue debt or equity securities for general corporate purposes, including debt repayment, investments, acquisitions, or business expansions.

Key Dates

Recommendation

Keywords

Health Insurance, Managed Care, SEC Filing, 10-Q, Financial Results, Earnings, Revenue, Net Income, EPS, Medical Costs, Medicaid, Medicare Advantage, ACA, CarelonRx, Carelon Services, Antitrust Litigation, Star Ratings, Risk Adjustment, Healthcare Policy, Capital Resources, Stock Repurchase, Dividends, Acquisitions, Divestitures, Business Efficiency Program, Financial Instruments, Debt-to-Capital Ratio